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ABSTRACT
Alterations within the RAS (renin–angiotensin system) are pivotal for the development of renal
disease. ACE2 (angiotensin-converting enzyme 2) is expressed in the kidney and converts the
vasoconstrictor AngII (angiotensin II) into Ang-(1–7), a peptide with vasodilatory and anti-ﬁbrotic
actions. Although the expression of ACE2 in the diabetic kidney has been well studied, little
is known about its expression in non-diabetic renal disease. In the present study, we assessed
ACE2 in rats with acute kidney injury induced by STNx (subtotal nephrectomy). STNx and
Control rats received vehicle or ramipril (1 mg · kg−1 of body weight · day−1), and renal ACE,
ACE2 and mas receptor gene and protein expression were measured 10 days later. STNx rats
were characterized by polyuria, proteinuria, hypertension and elevated plasma ACE2 activity (all
P<0.01) and plasma Ang-(1–7) (P<0.05) compared with Control rats. There was increased
cortical ACE binding and medullary mas receptor expression (P<0.05), but reduced cortical and
medullary ACE2 activity in the remnant kidney (P<0.05 and P<0.001 respectively) compared
with Control rats. In STNx rats, ramipril reduced blood pressure (P<0.01), polyuria (P<0.05)
and plasma ACE2 (P<0.01), increased plasma Ang-(1–7) (P<0.001), and inhibited renal ACE
(P<0.001). Ramipril increased both cortical and medullary ACE2 activity (P<0.01), but reduced
medullary mas receptor expression (P<0.05). In conclusion, our results show that ACE2 activity
is reduced in kidney injury and that ACE inhibition produced beneﬁcial effects in association with
increased renal ACE2 activity. As ACE2 both degrades AngII and generates the vasodilator Ang-
(1–7), a decrease in renal ACE2 activity, as observed in the present study, has the potential to
contribute to the progression of kidney disease.
INTRODUCTION
Alterations within the RAS (renin–angiotensin system)
are pivotal for the development and progression of renal
disease [1,2]. ACE2 (angiotensin-converting enzyme 2)
[3–5]isarecentlydiscoveredmonocarboxypeptidasethat
regulatesRASthroughdegradationofthevasoconstrictor
andpro-ﬁbroticpeptideAngII(angiotensinII)intoAng-
(1–7) [angiotensin-(1–7)], a peptide reported to have
vasodilatory and anti-ﬁbrotic actions [6,7] via actions at
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the Ang-(1–7) or mas receptor [8]. In normal physiology,
ACE2 is highly expressed in the kidney and has been
localized to the glomerulus, where it is expressed in
podocytes and mesangial cells [9,10], and to the proximal
tubules [11]. ACE2 is also expressed in the medulla in
collecting ducts and the vasa rectae [12].
Previous studies have suggested that the expression
of ACE2 may be an important determinant of injury
[11,13,14], and the therapeutic potential of increased
ACE2 activity has now been recognized [15,16]. Cer-
tainly, in renal disease, ACE2 may have renoprotective
effects, as when ACE2 is deleted or inhibited renal
pathology ensues, presumably because of the removal of
a degradative pathway for AngII. For example, ACE2-
knockout mice develop glomerulosclerosis, which can
be prevented by angiotensin receptor blockade [17],
and pharmacological inhibition of ACE2 in the spon-
taneouslydiabetic(db/db)mouseacceleratesalbuminuria
and glomerulosclerosis [9] and causes glomerular injury
in STZ (streptozotocin)-induced diabetes [18]. In
addition, ACE2-knockout mice crossed with a model
of Type 1 diabetes also had accelerated kidney injury
that was ameliorated by an ARB (angiotensin receptor
blocker) [19].
As both diabetic and non-diabetic renal disease are
associated with an overactive intrarenal RAS [1], we
were interested in the potential role of ACE2 in
non-diabetic renal disease such as that induced by
STNx (subtotal nephrectomy), especially as signiﬁcant
increases in renal ACE and AngII occur after renal
mass reduction [20–22]. In this model, nephrons
are lost through surgical ablation and the remaining
nephrons undergo physiological changes, resulting in
hypertrophy and hyperﬁltration to compensate for the
nephron loss. Early after surgery [22,23], rats develop
hypertension, polyuria and proteinuria, whilst, over
more prolonged time periods, glomerulosclerosis and
tubular atrophy further accelerate nephron loss, and this
leads to chronic renal disease associated with a decrease
in creatinine clearance and tubulointerstitial ﬁbrosis
[20–22].
To characterize further the RAS in the kidney
and assess the potential involvement of ACE2 in the
pathophysiology that occurs after STNx, we examined
gene and protein expression as well as localization
of ACE2 in the kidney from Sprague–Dawley rats
without or with STNx, and compared this with changes
in the related enzyme ACE. In addition, the effect
of blocking ACE using the ACEI (ACE inhibitor)
ramipril on renal ACE, ACE2 and the mas receptor gene
and protein expression in Control and STNx rats was
assessed.
Part of this work was presented at the High Blood
Pressure Research Council of Australia Annual Scientiﬁc
meeting, held in Melbourne on 4–5 December 2008, and
subsequently published in abstract form [23a].
MATERIALS AND METHODS
Experimental protocol
Experimental procedures were performed in accordance
with the National Health and Medical Research Council
of Australia guidelines for animal experimentation, and
were approved by the Animal Ethics Committee, Austin
Health. Rats were housed in a 12 h/12 h light/dark cycle,
withadlibitumfoodcontaining0.4–0.6%NaCl(Norco)
and water. STNx (n=21) or sham surgery (Controls;
n=21) was performed in female Sprague–Dawley rats
(bodyweight,200–250 g),asdescribedpreviously[23].In
brief, rats were anaesthetized by intraperitoneal injection
of sodium pentobarbitone (60 mg/kg of body weight;
BoehringerIngelheim)andSTNxwasperformedbyright
nephrectomy, followed by infarction of approximately
two-thirds of the left kidney with selective ligation of
all but one of the extrarenal branches of the left renal
artery. Rats were randomly allocated to a vehicle-treated
group (n=10 for Control; n=9 for STNx) or an ACEI-
treated group (n=11 for Control; n=12 for STNx) for
10 days. The ACEI ramipril was administered by daily
gavage at a dose of 1 mg/kg of body weight. On day 9,
rats were housed in metabolic cages for 24 h to measure
water intake and urine output, and to collect samples
of urine for biochemical analysis and protein analysis.
On day 10, rats were anaesthetized by intraperitoneal
injection of sodium pentobarbitone (60 mg/kg of body
weight), and SBP [systolic BP (blood pressure)] was
measured via carotid artery cannulation. Rats were then
killed by a lethal dose of sodium pentobarbitone. The
remnant kidney was removed and weighed. A portion
of the kidney was ﬁxed in 4% paraformaldehyde and
embedded in parafﬁn for histopathology. The remainder
of the kidney was snap-frozen in 2-methylbutane and
storedat−80◦Cfortheinvitroautoradiographicstudies,
ACE2 activity assay and RNA extraction.
Biochemical analysis
Plasma and urinary urea and creatinine concentrations
were measured using an autoanalyser (Beckman In-
struments). Urinary protein was determined using the
BCA (bicinchoninic acid) method with a commercially
available BCA Protein Assay kit (Pierce).
Plasma Ang-(1–7) RIA
Blood samples for the determination of Ang-(1–7)
were collected into tubes containing 20 μlo fa n
inhibitor cocktail [50 mol/l Na2EDTA, 0.2 mol/l N-
ethylmaleimide and 1–2 TIU (trypsin inhibitor units)/ml
aprotinin made up in saline] per ml of blood. Plasma
was snap-frozen and stored at −80◦C. Ang-(1–7) was
measured by RIA, as described previously [24], using an
Ang-(1–7) antibody raised in guinea-pig and 125I-Ang-
(1–7) (Prosearch). The intra- and inter-assay coefﬁcients
of variation for the assay were 4.5 and 10% respectively.
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QRT–PCR (quantitative real-time–PCR)
Kidneys were dissected into cortex and medulla
(Control kidneys; n=7/group) or cortex, medulla
and scar (STNx remnant kidney; n=9–10/group).
Total RNA was isolated from the dissected kidneys
using the RNeasy kit method (Qiagen). cDNA was
synthesized with a reverse transcriptase reaction
using standard techniques (Superscript II kit; Life
Technologies) as described previously [11,13]. Primers
and probes were designed using the Primer Express
software program (PE Applied Biosystems) with
the following sequences: rat ACE 5  oligonucleotide
primer, 5 -CACCGGCAAGGTCTGCTT-3 ; ACE 3 
oligonucleotide primer, 5 -CTTGGCATAGTTTCGT-
GAGGAA-3 ; and ACE probe FAM (6-carboxyﬂu-
orescin)-5 -CAACAAGACTGCCACCTGCTGGTC-
C-3 -TAMRA(6-carboxytetramethylrhodamine);ACE2
5  oligonucleotide primer, 5 -GCCAGGAGAT-
GACCGGAAA-3 ; ACE2 3  oligonucleotide primer, 5 -
CTGAAGTCTCCATGTCCCAGATC-3 , and ACE2
probe, FAM-5 -TTGTCTGCCACCCCACA-3 -TAM-
RA; mas receptor 5  oligonucleotide primer, 5 -CATC-
TCTCCTCTCGGCTTTGTG-3 ;masreceptor3  oligo-
nucleotide primer, 5 -CCTCATCCGGAAGCAAA-
GG-3 ;a n dmas receptor probe, FAM-5 -CGGGATC-
CTCCTCTGG-3 -TAMRA. QRT–PCR was carried
out using a multiplex method with VIC (6-carboxy-
rhodamine)-labelled 18S as the endogenous control. A
relative expression method was applied in the present
study using the vehicle-treated control group as the
calibrator and all groups were compared with the
calibrator group, which was given a value of 1.
Kidney histopathology
Toassessglomerulosclerosisandtubulointerstitialinjury,
renal sections were stained with haematoxylin and eosin
and examined in a blinded fashion under high power
on a light microscope (magniﬁcation ×400). A total of
30 glomeruli and 20 ﬁelds of tubulointerstitial area were
graded using a semi-quantitative method [20].
Renal ACE activity
Renal ACE (n=5/group) was assessed on renal sections
(20 μm) using quantitative in vitro autoradiography and
the speciﬁc radioligand 125I-MK351A (Ki =30 pmol/l) as
reported previously [25]. Quantiﬁcation of two sections
from each rat was performed using a microcomputer-
imaging device (Imaging Research), and results are
expressed as a percentage of the binding in control rats.
QFS (quenched ﬂuorescent substrate)
assay of renal and plasma ACE2 activity
WehavedevelopedanassayforACE2enzymaticactivity
in tissue and plasma which has been validated using
Westernblotting[11,26]andimmunohistochemistry[13].
To measure renal ACE2 activity, kidneys were dissected
into cortex and medulla (Control kidneys) or cortex,
medulla and scar (STNx remnant kidney). The tissue
was homogenized in ice-cold TBS [Tris-buffered saline;
25 mmol/lTris/HCl(pH 7.4)and125 mmol/lNaCl],and
the homogenates were pelleted by ultracentrifugation
(45000 rev./min at 4◦C for 1 h in a TLA 100.2 rotor;
Beckman). Prior to the ACE2 activity assay, an aliquot
of each sample was diluted 10-fold in ACE2 assay buffer
[100 mmol/l Tris/HCl (pH 6.5) and 1 mol/l NaCl]. For
plasma ACE2 activity, blood collected into heparinized
tubes was centrifuged at 4◦C and assayed using an
ACE2-speciﬁc QFS [(7-methoxycoumarin-4-yl)-acetyl-
Ala-Pro-Lys (2, 4-dintirophenyl); Auspep] [23].
Expression of ACE2 and mas receptor
protein by immunohistochemistry
Immunohistochemical staining for ACE2 (polyclonal
antibody T17 diluted 1:100; Santa Cruz Biotechnology)
was performed in rat kidney sections as described
previously [13]. Mas receptor immunohistochemistry
was performed using a polyclonal mas proto-oncogene
antibody (diluted 1:5; Novus Biologicals). Sections
(4 μm) were rehydrated, blocked with 3% (v/v) H2O2
and 10% (v/v) normal goat serum before incubation
with primary antibody at 4◦C overnight. The secondary
antibody was goat anti-rabbit at a dilution of 1:400.
Antibody labelling was visualized using an avidin–
biotin complex (ABC kit; Vector Laboratories) and
DAB (diaminobenzidine) before counterstaining with
haematoxylin. The negative control for ACE2 and mas
receptor immunostaining was carried out by omission
of the primary antibody. Images were acquired on an
Olympus BX50 microscope (objective lens, ×20/0.50),
using a Leica DFC480 camera and Leica IM50Image
Manager.
Statistical analysis
Values are shown as means+ −S.E.M. Data were analysed
using a Student’s t test for comparison between the
vehicle- and ramipril-treated Control, vehicle-treated
Control and STNx, and between STNx and STNx with
ramiprilusingtheGraphPadPRISMprogram(GraphPad
Software). A P value <0.05 was considered statistically
signiﬁcant.
RESULTS
STNx model
Table 1 shows the changes in physiological and
biochemical parameters after STNx and the effect of
ACE inhibition with ramipril. Following STNx, rats had
poor weight gain (P<0.05), and developed increased
SBP (P<0.01) and hypertrophy of the remnant kidney
(P<0.001) compared with vehicle-treated Control rats.
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Table 1 End-organ weight, physiological parameters, and plasma and urine biochemistry
∗P <0.05, ∗∗P <0.01 and ∗∗∗P <0.001 compared with control vehicle; †P <0.05, ††P <0.01 and †††P <0.001 compared with the appropriate
vehicle-treated rats. Ramipril was administered at a dose of 1 mg · kg−1 of body weight · day−1.
Control STNx
Characteristic Vehicle (n=10) Ramipril (n=11) Vehicle (n=9) Ramipril (n=12)
Body weight (g) 218+ −2 213+ −4 203+ −5∗ 219+ −3†
SBP (mmHg) 131+ −5 111+ −3†† 179+ −9∗∗ 115+ −6††
Renal parameter
Left kidney weight (g) 0.765+ −0.015 0.808+ −0.017 1.027+ −0.028∗∗∗ 1.085+ −0.023
Left kidney/body weight (g/100 g) 0.351+ −0.008 0.379+ −0.008 0.506+ −0.014∗∗∗ 0.499+ −0.009
Water intake (ml · 100 g−1 · 24 h−1)1 3 + −11 6 + −12 6 + −3∗∗∗ 30+ −3
Urine volume (ml · 100 g−1 · 24 h−1)5 + −16 + −11 9 + −5∗∗∗ 11+ −2†
Urinary protein (mg/24 h) 22+ −23 6 + −4†† 37+ −4∗∗ 38+ −3
Creatinine clearance (ml/min) 1.3+ −0.2 1.4+ −0.2 1.5+ −0.2 1.3+ −0.1
Plasma parameter
Plasma creatinine (μmol/l) 36+ −44 2 + −53 3 + −34 1 + −3
Plasma urea (mmol/l) 7+ −19 + −16 + −18 + −1
Plasma ACE2 activity (nmol · ml−1 · h−1)5 . 5 + −0.4 5.7+ −0.5 8.0+ −0.7∗∗ 4.4+ −0.5††
Plasma Ang-(1–7) (fmol/ml) 142+ −14 1862+ −162†† 248+ −41∗ 1340+ −191†††
Figure 1 Relative quantiﬁcation of cortical (A and B) and medullary (C and D) ACE and ACE2 mRNA using QRT–PCR in
control or STNx rats with vehicle or ramipril treatment
∗P <0.05 compared with Control (n=7–10/group).
STNx rats had increased urine volume (P<0.001) and
proteinuria (P<0.01), with no change in plasma urea,
plasma creatinine or creatinine clearance compared with
Controls (Table 1). At this early stage of renal injury,
there was no evidence of tubulointerstitial ﬁbrosis or
glomerulosclerosis in the remnant kidney of the STNx
rats (results not shown), although more sophisticated
techniques may detect more subtle injury.
Ramipril improved weight gain in STNx rats
(P<0.05), but did not affect kidney hypertrophy
(Table 1). ACE inhibition signiﬁcantly decreased SBP in
bothControlandSTNxrats(P<0.01),andreducedurine
volume in STNx rats (P<0.05) but not in Control rats.
Ramipril had no effect on proteinuria in the STNx rats
and caused proteinuria in the Control rats. This effect
of ACE inhibition can also occur clinically early after
commencing treatment, but does not persist long-term
[27].
STNx increased plasma ACE2 activity and plasma
Ang-(1–7) (P<0.01 and P<0.05 respectively; Table 1)
compared with Control rats. Ramipril was associated
with a decrease in plasma ACE2 activity in STNx rats
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Table 2 ACE, ACE2 and mas receptor mRNA and ACE2
activity in scar tissue of the remnant kidney
Ramipril was administered at a dose of 1 mg · kg−1 of body weight · day−1.
STNx
Measurement Vehicle (n=7) Ramipril (n=10)
ACE mRNA (arbitrary units) 1.00+ −0.31 1.09+ −0.22
ACE2 mRNA (arbitrary units) 1.00+ −0.23 2.92+ −1.01
mas receptor mRNA (arbitrary units) 1.00+ −0.19 0.79+ −0.15
ACE2 activity (nmol · mg−1 of 6.0+ −1.2 7.8+ −1.2
protein · h−1)
(P<0.01), but plasma ACE2 activity was unchanged in
Control rats. Ramipril treatment signiﬁcantly increased
plasma Ang-(1–7) in both the Control and STNx rats
(P<0.01 and P<0.001 respectively; Table 1).
ACE and ACE2 mRNA expression
Figure 1 shows the relative quantiﬁcation of renal ACE
and ACE2 mRNA in the renal cortex and medulla in
Control and STNx rats. In the remnant kidney after
STNx, there was a reduction in ACE mRNA expression
in the cortex and medulla (Figures 1A and 1C) and a
decrease in ACE2 mRNA expression in the cortex but
not medulla (Figures 1B and 1D) compared with Control
kidneys.
Ramipril had no effect on ACE or ACE2 mRNA
expression in either STNx or Control kidneys (Figure 1).
No signiﬁcant changes in ACE or ACE2 mRNA in scar
tissue were observed (Table 2).
Renal ACE and ACE2 protein
Figure 2 shows an in vitro autoradiograph of ACE
radiolabelling in Control kidneys and STNx remnant
kidneys. In normal kidneys, ACE was localized to
the proximal tubules in the inner cortex, as reported
previously [28], with lower ACE binding detectable
in the medulla. After STNx, ACE activity increased
signiﬁcantly in the inner cortex (P<0.001). Ramipril
reduced ACE binding in both Control and STNx rats
(P<0.001; Figure 2B).
Figure 3 shows ACE2 activity measured in kidney
homogenates. In Control kidney, ACE2 activity was
detectable in both the renal cortex and medulla.
Interestingly, after STNx, ACE2 activity signiﬁcantly
decreasedinthecortex(P<0.05)andmedulla(P<0.001)
compared with vehicle-treated Control rats (Figures 3A
and 3B). Ramipril had no effect on renal ACE2 activity
in Control rats, but was associated with a signiﬁcant
increase in ACE2 activity in both the cortex and medulla
of STNx kidneys (P<0.01). No signiﬁcant changes in
ACE2 activity were observed in the renal scar tissue
(Table 2).
Figure 2 Localization and quantiﬁcation of ACE radio-
labelling in the rat kidney in Control or STNx rats with
vehicle or ramipril treatment
(A) In vitro autoradiograph showing ACE radiolabelling in the rat kidney. The
white colour denotes the highest density of labelling, whereas the black colour
represents background labelling. Sections from Control (Sham) rat kidney and STNx
kidney without and with ramipril treatment are shown. In the Control kidney,
there is abundant ACE radiolabelling of the inner cortex and outer stripe of the
outer medulla. STNx increases ACE radiolabelling, which was reduced by ramipril.
(B) Relative quantiﬁcation of ACE radiolabelling in the inner cortex of the rat
kidney expressed as a percentage of that in Control rats. ∗∗∗P <0.001 compared
with Control vehicle ###P <0.001 compared with appropriate vehicle-treated
rats (n=5/group).
Localization of ACE2 protein in the renal
cortex and medulla
The renal cortex comprises both glomeruli and tubules,
although the glomeruli comprise only approx. 5%
of the cortex; the medulla includes collecting ducts
and the vasa recta. Figure 4 shows the qualitative
immunohistochemical localization of ACE2 in the
kidney. ACE2 protein was present in the cortex,
predominantly, but not exclusively, localized to proximal
and distal tubules, and, in the medulla, ACE2 mainly
localized to the collecting ducts (Figure 4). Both
cortical (Figures 4A–4D) and medullary (Figures 4F–4I)
ACE2 immunostaining decreased after STNx, and
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Figure 3 ACE2 activity in the cortex (A) and medulla (B) of rat kidney in Control or STNx rats with vehicle or ramipril
treatment
∗P <0.05 and ∗∗∗P <0.001 compared with Control vehicle ##P <0.01 compared with STNx vehicle (n=7–10/group).
were qualitatively increased by ramipril treatment.
The changes in staining intensity observed with
ACE2 immunohistochemistry were consistent with the
measurementofrenalACE2activityasshowninFigure3.
mas receptor mRNA expression and
localization in the renal cortex
and medulla
Figure 5 (upper panel) shows the relative quantiﬁcation
of mas receptor mRNA in the renal cortex and medulla
of Control and STNx rats. In the remnant kidney after
STNx, mas receptor mRNA expression increased in the
renal medulla (P<0.05), but not in the cortex compared
with Control. Ramipril led to reduced medullary mas
receptor expression (P<0.05) with no changes in renal
cortex or scar tissue (Table 2).
Using qualitative immunohistochemistry (Figure 5,
lower panel), mas receptor protein was localized
predominantly to the basal and apical surfaces of distal
tubules in the cortex (Figures 5A–5D). Medullary mas
receptor protein was localized to the thin limb of Henle
and to cells between the tubules and capillaries, likely
to be renomedullary interstitial cells (Figure 5F–5I),
although further studies are needed to conﬁrm this.
Therewerenoqualitativechangesinmasreceptorprotein
expression in the STNx or ramipril-treated animals.
DISCUSSION
The major ﬁndings of the present study are that an acute
reduction in renal mass by STNx increases circulating
levels of the enzyme ACE2 and leads to a 50% decrease
in renal ACE2 enzymatic activity, which is accompanied
by a signiﬁcant increase in renal ACE activity of the
same order. After administration of ramipril to STNx
rats,the renal expressionofACE changed inthe opposite
direction to ACE2, so that as ACE decreased ACE2
activity was enhanced. Our results are consistent with
the notion that ACE2 may be playing a protective role in
the diseased kidney. As ACE2 both degrades AngII and
generates the vasodilator and anti-ﬁbrotic peptide Ang-
(1–7), a decrease in renal ACE2 activity, as observed in
the present study, has the potential to contribute to the
progression of renal injury. Support for this hypothesis
comes from a recent study in the mas receptor-knockout
mouse, where a lack of Ang-(1–7) action at the renal level
causedhyperﬁltration,proteinuriaandatendencytoward
glomerulosclerosis [29].
At this early stage (10 days post-STNx), there was no
evidence of glomerular or tubulointerstitial ﬁbrosis or a
decline in renal function, but rats were hypertensive with
polyuria and proteinuria. Ramipril lowered BP in both
Control and STNx rats and increased circulating levels of
Ang-(1–7) approx. 80-fold, which may contribute to the
antihypertensive effects observed. The elevated levels of
plasmaAng-(1–7)observedfollowingACEinhibitionare
duetothefactthatACEisresponsibleforthebreakdown
of Ang-(1–7), and the results are consistent with ﬁndings
fromothersstudiesthatalsoreportsigniﬁcantincreasesin
plasma Ang-(1–7) after ACE inhibition [30,31]. Ramipril
not only reduced BP, but also led to a signiﬁcant decrease
in urine volume in STNx but not in Control rats.
Interestingly,itwasonlyafterSTNxthatchangesinrenal
ACE2 activity with ramipril were observed.
To date the effects of RAS blockade on ACE2 gene
expression in the kidney have not been well studied, but
the results of the present study are in agreement with our
previous work in STZ-induced diabetes in the rat [11]. In
that study, renal pathology was associated with low renal
tubular ACE2 protein expression, and ACE inhibition
improved pathology in association with the restoration
of renal ACE2 levels; however, the changes in renal
ACE2 protein measured by Western blotting were not
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Figure 4 Light microscopic micrographs showing ACE2 immunohistochemical labelling (brown staining) of the rat kidney
cortex (A–E) and medulla (F–J) in Control or STNx rats with vehicle or ramipril treatment
Micrographs show staining of the tubules in the cortex from vehicle- and ramipril-treated Control (A and B), STNx (C) and ramipril-treated STNx (D) kidneys. Medullary
collecting ducts (CD) also stain ACE2 in vehicle- and ramipril-treated Control (F and G), STNx (H) and ramipril-treated STNx (I) kidneys. Immunohistochemical negative
(-ve) controls are shown in (E) and (J). DT, distal tubule; Gl, glomeruli; PT, proximal tubules.
reﬂected by changes inACE2 mRNA [11]. Inthe present
study,ACE2proteinwasmeasuredusingaspeciﬁcACE2
catalytic activity assay as well as immunostaining, and
again no correlation between renal ACE2 activity
and ACE2 gene expression was found. Discrepancies
between ACE2 mRNA and protein/activity in the renal
cortex have also been reported in the spontaneously
diabetic mouse (db/db) and in STZ diabetic mice [32,33].
The relative effects of RAS blockade on ACE2
expression are also inconsistent. One group reports that,
in the renal vasculature of mice, both ACE2 mRNA
and protein expression increased after administration
of the ARB telmisartan [10], but others have shown
no effect of ACE inhibition or angiotensin receptor
blockade on ACE2 mRNA in the kidney of normal rats
[30]. The results suggest that the regulation of ACE2
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Figure 5 For legend see facing page
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.ACE2 and renal injury 277
may vary according to cell type, as well as the disease
and the prevailing BP. It also appears that, in some
circumstances, ACE2 is altered at a post-transcriptional
level. Taken together, the ﬁndings highlight the need for
studies to assess not only ACE2 mRNA, but also ACE2
activity/protein.
A strength of the present study was the examination of
the expression of ACE2 at the gene and protein level in
both the cortex and medulla of the kidney. The cortex
comprises both glomeruli and proximal tubules, but,
as the glomeruli make up only 5% of cortical mass,
changes in cortical ACE2 reﬂect changes occurring in
the proximal tubule. In general, most groups use the
cortex for RNA and protein preparations [32,33] or have
sieved the preparations to separate glomeruli and tubules
[11]. However, ACE2 is also present in the renal medulla
[12], which is a structure that plays an important role in
maintaining body ﬂuid and electrolyte balance, and BP
homoeostasisthroughtheactionsofvasoactivehormones
to inﬂuence medullary/papillary blood ﬂow and urinary
water and sodium excretion [34–36].
The regulation of ACE2 in the medulla in renal disease
has not been assessed previously. We found that ACE2
was localized to the medullary collecting ducts, where
its role to generate Ang-(1–7) may in turn regulate
water transport through an interaction with the Ang-
(1–7) or mas receptor [37]. It is known that Ang-(1–7)
exerts anti-diuretic effects [38,39], and Ang-(1–7) re-
ceptor blockade results in diuresis and natriuresis [40].
Moreover, in transgenic rats overexpressing Ang-(1–7),
urinary ﬂow is decreased [41]. As mentioned above, we
haveobservedareductioninACE2activityinthemedulla
in STNx rats, which also had polyuria. Although we
were not able to measure renal Ang-(1–7) peptide levels,
the reduction in medullary ACE2 might be expected to
decrease renal Ang-(1–7) and increase urine ﬂow. The
ﬁnding of an increased expression of the mas receptor
in the renal medulla in STNx would be consistent
with this speculation, as would the observation that
restoration of renal medullary ACE2 activity and mas
receptor expression following ACE inhibition reduced
urine volume.
Our results also highlight that tissue-speciﬁc changes
in ACE2 occur in renal disease. The reduction in renal
ACE2 activity in STNx contrasts with our previous
work that demonstrated increased cardiac ACE2 activity
in STNx [23]. Other investigators have observed a
similar discordance in other experimental models; in
the db/db mouse, ACE2 activity was increased in the
kidney cortex but not the heart [32]. It is likely that the
expression of ACE2 may be speciﬁc for each model as
well as each organ, and importantly may be dependent
on the time point studied. In this model of renal
injury, the STNx rats had polyuria and proteinuria,
but at this early hyperﬁltering stage rats were able
to maintain normal creatinine clearance. In long-term
studies in STNx, rats develop worsening renal function
as well as histological changes in glomerulosclerosis
and tubulointerstitial ﬁbrosis. Future studies should
investigate whether the renal changes in ACE2 and the
mas receptor observed 10 days after renal injury are
maintained over the long-term and, indeed, contribute
to the development of complications and the progression
of disease.
The present study also highlights the problem of
interpretingplasmaACE2levelsinthecontextofchanges
in ACE2 at the tissue level. The major contribution to
plasma ACE2 levels is from shedding of the enzyme
from the major sites of ACE2 expression, the heart and
kidney [42]. We have shown previously that both plasma
and cardiac ACE2 are elevated following STNx [23] and,
in the present study, we report increased plasma ACE2
activity in the context of decreased renal ACE2. Taken
together,ourresultssuggeststhatcirculatingACE2levels
are indicative of cardiac rather than renal ACE2 levels in
STNx. Support for this comes from the results of the
ACEI treatment arm; as ACE2 activity is not inhibited
by ACEIs [42], any change in plasma ACE2 activity is
likely to reﬂect changes at the tissue level. The ﬁnding
that ramipril treatment was associated with a reduction
inbothplasmaandcardiacACE2levelsinSTNx[23],but
an increase in renal ACE2 activity, would support this.
It is currently unclear how the perturbations in tissue
and circulating levels of ACE2 observed in an animal
modelofrenaldiseaserelatetotheclinicalsetting.Several
studies have assessed ACE2 in human renal disease,
with inconsistent results. One study has shown that
ACE2 immunostaining was increased in the glomeruli
and peritubular capillaries in a variety of renal diseases
in humans [43]. More recently, however, a signiﬁcant
Figure 5 Quantiﬁcation and localization of the mas receptor in the cortex and medulla in Control or STNx rats with vehicle
or ramipril treatment
Upper panels, relative quantiﬁcation of cortical (A) and medullary (B) mas receptor mRNA using QRT–PCR in Control or STNx rats with vehicle or ramipril
treatment. ∗P <0.05 compared with Control; #P <0.05 compared with STNx (n=7–10/group). Lower panels, light microscopic micrographs showing mas receptor
immunohistochemical labelling (brown staining) in the rat kidney cortex (A–E) and medulla (F–J). Micrographs show staining of apical and basal membranes of distal
tubules (DT) from Control (A), ramipril-treated Control (B), STNx (C) and ramipril-treated STNx (D) kidneys. Collecting ducts (CD), medullary thin limbs of Henle (TL)
and cells between the tubules also stain for the mas receptor in Control (F), ramipril-treated Control (G), STNx (H) and ramipril-treated STNx (I) kidney medulla. Gl,
glomeruli; PT, proximal tubules. Immunohistochemical negative (-ve) controls are shown in (E) and (J).
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decrease in ACE2 gene and protein expression, and an
increaseinACEmRNA,werereportedincorticaltubules
from diabetic patients, but not in those with either focal
glomerulosclerosisorchronicallograftnephropathy[14].
Mizuri et al. [44] also showed decreased ACE2 and
increased ACE expression in the tubulointerstitium and
glomeruli of patients with overt diabetic nephropathy.
Although these results may suggest that only diabetic
kidney disease is associated with a reduction in ACE2
gene and protein expression, other investigators have
found that ACE2 expression is similar in renal biopsies
from patients with diabetes, primary glomerular disease,
nephrosclerosis and lupus [45].
In conclusion, the emerging evidence suggests that the
carboxypeptidase ACE2 serves as a negative regulator
of RAS and acts to counterbalance the actions of ACE
by regulating tissue AngII levels. As the injury in renal
disease is modulated, in part, by enhanced ACE activity
leading to increased AngII levels, a reduction in renal
ACE2activityand,hence,thelossofapathwayforAngII
peptide degradation may contribute to the progression
of renal injury. The lack of generation of a potentially
renoprotective peptide, Ang-(1–7), may also contribute
to ongoing renal damage. Strategies that amplify renal
ACE2expressionorsynthesismaybeausefultherapeutic
option in kidney disease, and the recent description
of small-molecule ACE2 activators [46] will allow this
approach to be tested, at least in experimental models.
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